Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Delayed First Injection Of The Once-a-month Injectable Contraceptive Containing 25 Mg Of Medroxyprogesterone Acetate And 5 Mg Of E(2)-cypionate: Effects On Ovarian Function.
Author: Petta, C A
Hays, M
Brache, V
Massai, R
Hua, Y
Alvarez-Sánchez, F
Croxatto, H
d'Arcangues, C
Cook, L A
Bahamondes, L
Abstract: To assess whether women who were administered the first injection of DMPA+E(2)C on day 7 of their menstrual cycle (delayed injection) exhibit the same degree of ovarian suppression as women who receive it on day 5 of their menstrual cycle. Multicenter, randomized controlled trial. Reproductive health clinics. Women aged between 18 and 38 years (inclusive) willing to use DMPA+E(2)C as their method of contraception. Participants received a DMPA+E(2)C injection on day 5 (control group, n = 41) or day 7 (delayed-injection group, n = 117) of their menstrual cycle. Ovarian activity and follicular development determined by serial serum progesterone levels and vaginal ultrasound. Participants who received DMPA+E(2)C on day 5 of their menstrual cycle (control group) exhibited no more than limited follicular growth (no follicle >16 mm). Of those women who received DMPA+E(2)C on day 7 of their menstrual cycle (delayed-injection group), 21 (18%) showed some follicular growth, of whom 4 (3%) ovulated. The first injection of DMPA+E(2)C given on day 7 of a menstrual cycle does not provide the same inhibition of ovarian activity as that observed when it is administered on day 5 of the menstrual cycle.
Subject: Adolescent
Age Factors
Body Mass Index
Contraceptive Agents, Female
Delayed-action Preparations
Medroxyprogesterone Acetate
Menstrual Cycle
Ovarian Follicle
Citation: Fertility And Sterility. v. 75, n. 4, p. 744-8, 2001-Apr.
Rights: fechado
Date Issue: 2001
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_11287029.pdf83.74 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.